Sign In
Buy VTVT
$32.35
-0.330 (-1.01%)
At Close: Jul 31, 2026
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
08:00am, Wednesday, 11'th Jun 2025
HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in
HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update
04:01pm, Thursday, 15'th May 2025
Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOB
Topline CATT1 Phase 3 data is expected in 2H 2026 Protocol amendment shortens trial duration from 12 to 6 months, expediting time to topline data HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
05:35pm, Thursday, 20'th Mar 2025
Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appo
FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges
01:59pm, Monday, 17'th Mar 2025
On Monday, the U.S. Food and Drug Administration (FDA) lifted the clinical hold on vTv Therapeutics Inc.'s VTVT cadisegliatin clinical program.
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
08:30am, Monday, 17'th Mar 2025
Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall durati
WESTON, Fla. , Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening m
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
04:05pm, Monday, 02'nd Dec 2024
HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in dia
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
04:15pm, Thursday, 08'th Aug 2024
Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global li
Why Is vTv Therapeutics (VTVT) Stock Down 46% Today?
08:33am, Monday, 29'th Jul 2024
VTv Therapeutics (NASDAQ: VTVT ) stock is falling hard on Monday after the Food and Drug Administration (FDA) placed a clinical hold on its cadisegliatin clinical program. According to a news release
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
04:05pm, Friday, 26'th Jul 2024
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead progr
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
04:05pm, Monday, 24'th Jun 2024
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
08:00am, Tuesday, 28'th May 2024
WESTON, Fla. , May 28, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening m
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
04:51pm, Thursday, 09'th May 2024
HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for t
